CARIS LIFE SCIENCES, INC. Expense Breakdown
No Expense Breakdown for CAI on this site yet.
- 2026-06-30: Molecular Profiling Services $81.33M; Pharma Research and Development Services $2.79M.
- 2025-06-30: Molecular Profiling Services $65.32M; Pharma Research and Development Services $2.39M.
Source checked: the stored Expense Breakdown page for CAI.
Expenses by product
Cost of sales: each quarter (3 month)
| Quarter end | Molecular Profiling Services | Pharma Research and Development Services |
|---|---|---|
| 2026-06-30 | $81.33M | $2.79M |
| 2025-06-30 | $65.32M | $2.39M |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RadNet, Inc. (RDNT) | United States | $5.611B | -229.65 |
| GRAIL, Inc. (GRAL) | United States | $5.591B | -7.78 |
| VERACYTE, INC. (VCYT) | United States | $3.904B | 41.21 |
| Celcuity Inc. (CELC) | United States | $3.887B | -22.62 |
| CareDx, Inc. (CDNA) | United States | $3.174B | 13.21 |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| Personalis, Inc. (PSNL) | United States | $1.769B | -13.30 |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |